Medtronic (XSWX:MDT) Other Financing: CHF35 Mil (TTM As of Apr. 2026)


XSWX:MDT Medtronic PLC XSWX:MDT
21 GF Score
Price CHF65.29
GF Value CHF80.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic Other Financing?

Medtronic XSWX:MDT +1.21% 21 Other Financing is CHF35 Mil as of Apr. 2026. GuruFocus rates XSWX:MDT with a GF Score™ of 21/100 and a GF Value™ of CHF80.97 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Medtronic's Other Financing for the three months ended in Apr. 2026 was CHF-13 Mil.

Medtronic's Other Financing for the trailing twelve months (TTM) ended in Apr. 2026 was CHF35 Mil.

Medtronic Other Financing Historical Data

* Premium members only.

The historical data trend for Medtronic's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic Other Financing Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 154.04 -367.49 -2.73 -153.40 33.87

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -233.44 55.92 -3.99 -4.74 -12.60
XSWX:MDT
21GF Score
Medtronic PLC XSWX:MDT
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of CHF35 Mil mean?
Medtronic (XSWX:MDT) has a Other Financing of CHF35 Mil as of Apr. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Medtronic and its competitors.
Is Medtronic's Other Financing too high?
Medtronic's current Other Financing is CHF35 Mil. Overall, Medtronic has a GF Score™ of 21/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Other Financing compare to SYK and BSX?
Medtronic's Other Financing of CHF35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Medtronic and its competitors. Medtronic's current Other Financing is CHF35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (XSWX:MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF80.97, compared to a current price of CHF65.29 — trading 19.4% below its estimated fair value. The current Other Financing is CHF35 Mil. Medtronic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Medtronic (XSWX:MDT), the current Other Financing is CHF35 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (XSWX:MDT) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of CHF65.29 is trading 19.4% below its estimated GF Value™ of CHF80.97. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for XSWX:MDT:

  • Other Financing: CHF35 Mil
  • GF Value™: CHF80.97 vs. price of CHF65.29 (19.4% below fair value)
  • GF Score™: 21/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
21GF Score

Get the complete analysis for XSWX:MDT

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF65.29
Price
CHF80.97
GF Value